rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ONC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
      Nov 17BenzingaONC
      Jefferies reiterates Buy on BeOne Medicines stock, $470 target
      Nov 17Investing.comONCJEF
      BeOne Medicines at Jefferies: oncology shift broadens beyond BRUKINSA
      Nov 17Investing.comONCJEF
      Titus Ball Takes Money Off The Table, Sells $632K In BeOne Medicines Stock
      Nov 11BenzingaONC
      Breakingviews - COMMENTARY: Biotech rising star has lifeline from geopolitics
      Nov 9ReutersONC
      BeOne Medicines Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceONC
      BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion in U.S. ...
      Nov 5Yahoo FinanceONC
      Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
      Nov 5Yahoo FinanceONC
      Jefferies raises BeOne Medicines stock price target on solid quarter
      Nov 5Investing.comONC
      BeOne Medicines DRC earnings beat by $2.66, revenue topped estimates
      Nov 5Investing.comONC
      BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma
      Nov 4Yahoo FinanceONC
      BeOne wins FDA priority review for Brukinsa label update (ONC)

      BeOne Medicines (ONC) stock gains as the FDA grants priority review for cancer therapy Brukinsa in newly diagnosed mantle cell lymphoma. Read more here.

      Nov 4Seeking AlphaONC
      Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
      Nov 3Yahoo FinanceONC
      If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
      Oct 30BenzingaONC
      BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative
      Oct 24Yahoo FinanceONC
      BeOne reports extended survival data from cancer drug trial
      Oct 23Investing.comONC
      BeOne Medicines Stock: Brukinsa And Tevimbra Face A High Bar (NASDAQ:ONC)
      Oct 23Seeking AlphaONC
      BeOne Medicines Sets Date for Q3 2026 Results and Investor Call

      Tipranks Press Release.

      Oct 23The Globe and MailONC
      With Visions Of 177% Earnings Growth, This Biotech Breaks Out

      Oncology-focused biotech firm BeOne pops into in buy range.

      Oct 22Investor's Business DailyONC
      BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
      Oct 22Yahoo FinanceONC
      Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cullinan Management (CGEM) and BeOne Medicines (ONC)

      Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailBWAYONC
      BeOne Medicines to Present New Solid Tumor Clinical Data Across Four Priority Programs at ESMO 2026
      Oct 19Yahoo FinanceONC
      BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
      Oct 19Yahoo FinanceONC
      Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
      Oct 15ReutersONCRVMD
      BeOne Medicines’ Multi-Timeframe Setup Points to a Broader Bullish Re-Rating
      Oct 15Investing.comONC
      All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
      Oct 15Yahoo FinanceONC
      BeOne Medicines (ONC) Surged on Strong Financial Performance and Upgraded Guidance

      Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2026 investor letter for the “Baird Chautauqua International and Global Growth Fund”. The letter can be downloaded here. The broad equity markets posted modest gains in the third quarter, despite significant volatility and rotation beneath the surface. […]

      Oct 13Yahoo FinanceONC
      Truist Financial Remains a Buy on BeOne Medicines (ONC)

      Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailONC
      China wants 5 innovative drugs with US$1b returns by 2030. Which might they be?

      Beijing is attempting to have at least five pharmaceutical products with annual global sales of more than US$1 billion.

      Oct 10South China Morning PostONC
      BeOne Medicines Successfully Completes Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® in first-line Recurrent or Metastatic Nasopharyngeal Carcinoma

      BeOne Medicines, a global oncology company, today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® (tislelizumab for injection) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

      Oct 6Yahoo FinanceONC
      Onco360® Has Been Selected as a National Specialty Pharmacy Partner for BEQALZI™ (sonrotoclax)
      Oct 6Yahoo FinanceONC
      Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

      Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.

      Oct 1Investor's Business DailyONC
      BeOne Medicines Ltd (6160) Receives a Buy from DBS

      Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailONC
      BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
      Sep 17BenzingaONC
      BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth
      Sep 14Investing.comONCMS
      BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

      BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...

      Sep 5Yahoo FinanceONC
      The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

      BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...

      Sep 5Yahoo FinanceONC
      BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

      BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]

      Sep 4Yahoo FinanceONC
      FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

      On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, […]

      Sep 1Yahoo FinanceONC
      BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

      SAN CARLOS, Calif., September 01, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT.

      Sep 1Yahoo FinanceONC
      Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers

      Trump unveils new drug-pricing deals with pharma and biotechs to cut U.S. healthcare costs, with Medicaid most-favored-nation pricing.

      Sep 1Seeking AlphaONC
      BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

      SAN CARLOS, Calif., August 31, 2026--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scient

      Aug 31Yahoo FinanceONC
      White House strikes new drug-pricing deals
      Aug 31PoliticoONC
      BeOne Medicines Reaches US Accord on Drug Access, Domestic Manufacturing

      BeOne Medicines (ONC) voluntarily agreed with the US government to expand patient access to its canc

      Aug 31Yahoo FinanceONC
      Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)

      Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

      Aug 26The Globe and MailONC
      Jazz stock gains on FDA nod for cancer therapy (JAZZ:NASDAQ)

      Jazz Pharmaceuticals (JAZZ) stock rises as the FDA approves the company's cancer therapy developed with BeOne Medicines (ONC) and Zymeworks (ZYME). Read more here.

      Aug 25Seeking AlphaJAZZONCZYME
      BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

      Is it a good or bad thing when a stock experiences a golden cross technical event?

      Aug 25Yahoo FinanceONC
      BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
      Aug 25Yahoo FinanceONC

      This is the newest page. Registered accounts read further back.